Literature DB >> 9607062

Revaccination against hepatitis B virus of non-responding and low-responding infants immunised at birth. A parallel evaluation of rubella and tetanus vaccine.

C Belloni1, C Tinelli, P Orsolini, A Pistorio, A Avanzini, A Moretta, R Gulminetti, O Bogliolo, G Chirico, G Rondini.   

Abstract

The aim of the present study was to identify the true extent of the non-responsiveness in infants born from HBsAg-negative mothers, vaccinated against Hepatitis B Virus (HBV) at birth. Sixty-four non- and low-responding infants, selected from an initial cohort of 2009, were given two additional doses of recombinant HBV vaccine between the tenth and the twelfth month of age. A parallel evaluation was conducted on the response to anti-rubella and anti-tetanus vaccine. Only two infants remained non-responders, whereas 68% of the non-responders and 94% of the low responders after the primary vaccination schedule developed antibody titres over 100 mIU ml-1. No significant relationship between the specific antibody level against HBV and against rubella or tetanus 1 month after vaccination was observed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607062     DOI: 10.1016/s0264-410x(97)80917-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Revaccination of non-responding infants delivered by HBsAg-positive mothers.

Authors:  M R Hasanjani Roushan; Y Zahed Pasha; R Saghebi; F Kohi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

2.  Revaccination of non- and low- responders after a standard three dose hepatitis B vaccine schedule.

Authors:  Ke Han; Xiaoping Shao; Huizhen Zheng; Chenggang Wu; Jianqiong Zhu; Xiaoli Zheng; Yonghui Zhang
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

Review 3.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.